A previous NCCN Oncology Insights Report described the factors making cancer care a priority for managed care organizations (MCOs) and emerging trends in managing costs of cancer care.1 To better understand the concerns of MCOs and how they are addressing cancer costs and quality, NCCN interviewed senior physician executives from the 3 largest payors in the United States. The interviews provided insights into how these companies managed oncology care, with an emphasis on drugs and biologics.
As a follow-up to the previous report, NCCN conducted additional interviews with medical executives from 10 MCOs between February and April 2010. The organizations represented in these interviews were Aetna, BlueCross BlueShield of Minnesota, BlueShield of Michigan, CareFirst BlueCross BlueShield, Empire BlueCross BlueShield, HealthNow, Humana, Independence BlueCross, Priority Health, and UnitedHealthcare. Although this group is diverse, it does not constitute a representative cross-section of MCOs across the United States. NCCN interviewed these executives about the priority of cancer care management for their organizations and the strategies being used to address cost and quality of cancer care. The information garnered from these interviews was qualitative in nature. A separate quantitative analysis of trends in oncology managed care has already been published, and throughout this report, data from the 2009–2010 Genentech Oncology Trend Report (GOTR) are referenced to supplement findings from the NCCN interviews.2
NCCN Oncology Insights Reports: Managed Care and Medical Oncology: Cancer is Now on the Table Report 1.2009. Available at: http://www.nccn.org/network/business_insights/oncology_trends/manged_care.asp. Accessed July 8 2010.
EmighR ed. The 2009–2010 Genentech Oncology Trend Report: Perspectives From Managed Care Specialty Pharmacy Providers Oncologists and Practice Managers. 2nd edition. South San Francisco, CA: Genentech; 2010.
Express Scripts. 2009Drug Trend Report. Available at: http://www.express-scripts.com/research/studies/drugtrendreport/2009/dtrFinal.pdf. Accessed August 3 2010.
Bristol Myers-Squibb. Biotechnology Monitor and Survey: Marketplace policies practices and perspectives: 2009. Available at: http://www.nxtbook.com/nxtbooks/emron/bms09/index.php#/0. Accessed August 3 2010.
Patient Protection and Affordable Care Act (PPACA). Available at: http://democrats.senate.gov/reform/patient-protection-affordable-care-act-as-passed.pdf. Accessed August 3 2010.
DiVarcoS. Health Care Reform: quality initiatives—the thread that ties it all together. Available at: http://www.mwe.com/index.cfm/fuseaction/publications.nldetail/object_id/21970108-acee-48b5-b82f-dda8cad89656.cfm. Accessed June 29 2010.
The Henry J. Kaiser Family Foundation. Focus on Health Reform. Summary of New Health Reform Law. Available at: http://www.kff.org/healthreform/upload/8061.pdf. Accessed June 28 2010.
DavisGSRichJP. Health Care Reform: ACOs and Developments in Coordinated Care Delivery Shared Savings and Bundled Payments. Available at: http://www.mwe.com/index.cfm/fuseaction/publications.nldetail/object_id/6699b22c-127a-4cf0-a80b-bab7a75767de.cfm. Accessed June 29 2010.
GlassDStenslandJ. Accountable Care Organizations. Available at: http://www.medpac.gov/transcripts/0408_ACO_public_pres.pdf. Accessed June 29 2010.
U.S. Department of Health and Human Services. Centers for Disease Control and Prevention. National Center for Health Statistics. Health United States 2009. Table 142. Available at: http://www.cdc.gov/nchs/data/hus/hus09.pdf#142. Accessed June 29 2010.
LiEDeMartinoJ. Preliminary report: the development of the “NCCN Comparative Therapeutic Index™” as a clinical evaluative process for existing data in oncology. J Natl Compr Canc Netw2010;8(Suppl 5):S1–10.